MiracleFeet Adds Two New Board Members

We are thrilled to introduce our new board members – Dr. Amrit Ray and Jarret Fass!

Dr. Ray currently serves as Chief Medical Officer of Janssen Pharmaceuticals, a division of Johnson & Johnson. He is a patient-focused Physician Researcher who advocates for innovation in areas of unmet medical need. With J&J since 2009, he is Chief Medical Officer for pharmaceuticals with global responsibility for the safe use of 1,000+ medicines, and for supporting an innovative research pipeline. After starting as a hospital doctor in Britain’s NHS, Dr. Ray has spent the last two decades specializing in driving research programs in industry and held growing executive roles. He has been recognized for pioneering bioethical policies and R&D for a number of new medicines, and been called to provide expert input to the US Congress, WHO and other leadership forums. He holds B.Sc. (Hons) and MD degrees from Edinburgh University, and is a former McKinsey consultant with an MBA from Dartmouth.

Jarret Fass is co-founder and Managing Partner of Pierpoint Capital, a technology and healthcare-focused private equity firm. He currently serves on the board of Hospital IQ, a predictive operational analytics platform and on the board of an Israel-based cardiovascular medical device company that he also co-founded. Jarret previously was a Principal at Selway Capital, a technology-focused multi-stage private equity firm sponsored by Columbus Nova, a $15 billion family office. Jarret began his career at Bear Stearns where he worked in the Corporate Strategy Group responsible for firm-wide growth initiatives including acquisitions, joint ventures and principal investments. Jarret holds a BA from Connecticut College and an MBA from Columbia Business School. He was born with bilateral clubfoot.

“All of us at MiracleFeet are driven by the shared desire to make a difference in the lives of children,” said Executive Director Chesca Colloredo-Mansfeld. Amrit and Jarret’s deep experience and passion for creating change will make us a stronger organization, and help us to ensure that all children born with clubfoot receive treatment, no matter where in the world they live.”